Brief: Newron Pharmaceuticals: Commercialization Partner Zambon With Valeo Pharma Announce Approval Of Onstryv® (Safinamide) For Parkinson’S Disease In Canada
16/01/2019 12:02
Jan 16 (Reuters) - NEWRON PHARMACEUTICALS SPA NWRN.S :
* NEWRON PHARMACEUTICALS: COMMERCIALIZATION PARTNER ZAMBON
TOGETHER WITH VALEO PHARMA ANNOUNCE THE APPROVAL OF ONSTRYV®
(SAFINAMIDE) FOR PARKINSON’S DISEASE IN CANADA
Source text for Eikon: ID:nBw1SxybGa
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study